As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus.
Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late-October 2022. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.